- Home
- CRVL vs ACAD Comparison
CRVL vs ACAD Comparison
Compare CRVL & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVL
- ACAD
- Stock Information
- Founded
- CRVL 1987
- ACAD 1993
- Country
- CRVL United States
- ACAD United States
- Employees
- CRVL N/A
- ACAD N/A
- Industry
- CRVL Specialty Insurers
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- CRVL Finance
- ACAD Health Care
- Exchange
- CRVL Nasdaq
- ACAD Nasdaq
- Market Cap
- CRVL 4.4B
- ACAD 4.3B
- IPO Year
- CRVL 1991
- ACAD 2004
- Fundamental
- Price
- CRVL $73.93
- ACAD $21.58
- Analyst Decision
- CRVL
- ACAD Buy
- Analyst Count
- CRVL 0
- ACAD 21
- Target Price
- CRVL N/A
- ACAD $29.25
- AVG Volume (30 Days)
- CRVL 201.7K
- ACAD 2.3M
- Earning Date
- CRVL 11-04-2025
- ACAD 11-05-2025
- Dividend Yield
- CRVL N/A
- ACAD N/A
- EPS Growth
- CRVL 27.81
- ACAD 615.00
- EPS
- CRVL 1.93
- ACAD 1.33
- Revenue
- CRVL $918,578,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- CRVL N/A
- ACAD $14.01
- Revenue Next Year
- CRVL N/A
- ACAD $11.81
- P/E Ratio
- CRVL $38.66
- ACAD $16.25
- Revenue Growth
- CRVL 12.46
- ACAD 14.41
- 52 Week Low
- CRVL $72.15
- ACAD $13.40
- 52 Week High
- CRVL $128.61
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- CRVL 28.39
- ACAD 34.96
- Support Level
- CRVL $72.90
- ACAD $21.32
- Resistance Level
- CRVL $75.14
- ACAD $21.85
- Average True Range (ATR)
- CRVL 2.07
- ACAD 0.63
- MACD
- CRVL -0.35
- ACAD -0.14
- Stochastic Oscillator
- CRVL 12.92
- ACAD 32.32
About CRVL CorVel Corp.
CorVel Corp applies technology including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. It partners with employers, third-party administrators, insurance companies, and government agencies in managing worker's compensation and health, auto, and liability services. The company's solutions combine integrated technologies with a human touch providing services that include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and medicare services.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.